Washington, DC, United States

Georgetown University

www.georgetown.edu
Washington, DC, United States

Georgetown University is a private research university in Washington, D.C. Founded in 1789, it is the oldest Catholic college or university in the United States, and so the oldest Jesuit university in the country. Georgetown's main campus, located in Washington's Georgetown neighborhood, is noted for Healy Hall, a National Historic Landmark in the Romanesque revival style. Georgetown Law School is located on Capitol Hill and Georgetown has auxiliary campuses in Italy, Turkey, and Qatar.Georgetown's founding by John Carroll, as America's first Catholic bishop, realized earlier efforts to establish a Roman Catholic college in the province of Maryland that had been thwarted by religious persecution. The university expanded after the American Civil War under the leadership of Patrick Francis Healy, who came to be known as Georgetown's "second founder" despite having been born a slave by law. Jesuits have participated in the university's administration since 1805, a heritage Georgetown celebrates, but the university has always been governed independently of the Society of Jesus and of church authorities.The university has about 7,000 undergraduate and over 10,000 post-graduate students from a wide variety of religious, ethnic, and geographic backgrounds, including 130 foreign countries. The university's most notable alumni are prominent in public life in the United States and abroad. Among them are former U.S. President Bill Clinton, U.S. Supreme Court Associate Justice Antonin Scalia, dozens of U.S. governors and members of Congress, heads of state or government of more than a dozen countries, royalty and diplomats.Campus organizations include the country's largest student-run business and largest student-run financial institution. Georgetown's athletic teams, nicknamed the Hoyas, include a men's basketball team that has won a record-tying seven Big East championships, appeared in five Final Fours, and won a national championship in 1984. Wikipedia.


Time filter

Source Type

Patent
Georgetown University | Date: 2016-11-30

Methods and compositions provided herein relate to the treatment of cancer. In some embodiments, the compositions have utility in the treatment of cancers including glioblastoma multiforme and lung cancer.


Patent
Georgetown University | Date: 2016-12-19

A system and method are described for enhancing readability of document images by operating on each document individually. Monochromatic light sources operating at different wavelengths of light can be used to obtain greyscale images. The greyscale images can then be used in any desired image enhancement algorithm. In one example algorithm, an automated method removes image background noise and improves sharpness of the scripts and characters using edge detection and local color contrast computation.


Patent
Georgetown University and University of Rochester | Date: 2017-03-29

The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one sample from the subject to determine a value of the subjects exosomal profile or combined biomarker profile (lipids plus exosomal cargo) and comparing the value of the subjects exosomal or combined biomarker profile with the value of a normal exosomal or biomarker profile, respectively. A change in the value of the subjects exosomal or combined biomarker profile, including a change in the subjects exosomal or combined biomarker profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.


Patent
Georgetown University and University of Rochester | Date: 2017-04-05

The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subjects metabolite profile and comparing the value of the subjects metabolite profile with the value of a normal metabolite profile. A change in the value of the subjects metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.


Patent
Georgetown University and University of Rochester | Date: 2017-04-05

The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing the gene expression profile from peripheral blood leukocytes taken from the subject and comparing the value of the subjects gene expression profile with the value of a normal gene expression profile. A change in the value of the subjects gene expression profile, above or below normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.


Patent
Georgetown University and University of Rochester | Date: 2017-03-08

The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subjects lipidomic profile, and also analyzing the gene expression profile from leukocytes and comparing the value of the subjects biomarker profile (lipidomic profile plus gene expression profile) with the value of a normal biomarker profile. A change in the value of the subjects biomarker profile, including a change in the subjects biomarker profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.


Patent
Georgetown University | Date: 2017-07-19

The invention is directed to methods of promoting myelin formation in central nervous system (CNS) tissue in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of interleukin-4 induced gene 1 (IL4-i1) protein. The invention is also directed to methods of monitoring the progression of conditions marked by an impairment of myelin formation in the CNS comprising assessing the levels or activity of IL4-i1 in activated macrophages obtained from the subject.


Patent
Georgetown University | Date: 2016-05-06

Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.


Weiss R.G.,Georgetown University
Journal of the American Chemical Society | Year: 2014

A Perspective is presented on the history and current understanding of molecular gels and the factors that must be considered to characterize them. The abilities of the most important structural, dynamic, and rheological tools available currently to provide the information necessary to follow the formation of a molecular gel from its initial sol phase and then to define it at different distance and time scales are discussed. Approaches to determining a priori when a molecule will gelate a selected liquid, as well as possible methodologies for overcoming current limitations in understanding molecular gels, are presented. Finally, some of the many potential and realized applications for these materials are enumerated. © 2014 American Chemical Society.


Mitchell J.M.,Georgetown University
New England Journal of Medicine | Year: 2013

BACKGROUND: Some urology groups have integrated intensity-modulated radiation therapy (IMRT), a radiation treatment with a high reimbursement rate, into their practice. This is permitted by the exception for in-office ancillary services in the federal prohibition against self-referral. I examined the association between ownership of IMRT services and use of IMRT to treat prostate cancer. METHODS: Using Medicare claims from 2005 through 2010, I constructed two samples: one comprising 35 self-referring urology groups in private practice and a matched control group comprising 35 non-self-referring urology groups in private practice, and the other comprising non-self-referring urologists employed at 11 National Comprehensive Cancer Network centers matched with 11 self-referring urology groups in private practice. I compared the use of IMRT in the periods before and during ownership and used a difference-in-differences analysis to evaluate changes in IMRT use according to self-referral status. RESULTS: The rate of IMRT use by self-referring urologists in private practice increased from 13.1 to 32.3%, an increase of 19.2 percentage points (P<0.001). Among non-self-referring urologists, the rate of IMRT use increased from 14.3 to 15.6%, an increase of 1.3 percentage points (P = 0.05). The unadjusted difference-in-differences effect was 17.9 percentage points (P<0.001). The regression-adjusted increase in IMRT use associated with self-referral was 16.4 percentage points (P<0.001). The rate of IMRT use by urologists working at National Comprehensive Cancer Network centers remained stable at 8.0% but increased by 33.0 percentage points among the 11 matched self-referring urology groups. The regressionadjusted difference-in-differences effect was 29.3 percentage points (P<0.001). CONCLUSIONS: Urologists who acquired ownership of IMRT services increased their use of IMRT substantially more than urologists who did not own such services. Allowing urologists to self-refer for IMRT may contribute to increased use of this expensive therapy. Copyright © 2013 Massachusetts Medical Society.

Loading Georgetown University collaborators
Loading Georgetown University collaborators